

#3  
PATENTS 2-20-02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Leonard Harrison, et al

**Examiner:** Unassigned

**Serial No.:** Unassigned

**Docket:** 10308B

**Filed:** Herewith

**Dated:** January 7, 2002

**For:** IMMUNOREACTIVE AND  
IMMUNOTHERAPEUTIC MOLECULES

J1040 U.S. PTO  
10/040815  
01/07/02

Assistant Commissioner for Patents  
Washington, DC 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is respectfully requested that the following disclosures, which are also listed on the attached form PTO-1449 be made of record in the above-identified case.

1. WO 92/05446, published April 2, 1992;

---

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

"Express Mail" Mailing Label Number:  
Date of Deposit:

**EV 052766565 US**  
**January 7, 2002**

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Dated: January 7, 2002

  
Michelle Mustafa

2. WO 92/14485, published September 3, 1992;
3. WO 92/20811, published November 26, 1992;
4. WO 94/12529, published June 9, 1994;
5. WO 95/07464, published March 16, 1995;
6. WO 95/07992, published March 23, 1995;
7. Mauch, et al., (1992), "Characterization of a linear epitope within the human pancreatic 64-kDa glutamic acid decarboxylase and its autoimmune recognition by sera from insulin-dependent diabetes mellitus patients", Eur J.Biochem, vol 212:597-603; and
8. Daw et al., (1995), "Two Distinct Glutamic Acid Decarboxylase Auto-Antibody Specificities in IDDM Target Different Epitopes" Diabetes, Vol:44, pp 216-220.

Pursuant to 37 C.F.R. §1.98(d), copies of the above listed publications are not provided, as the references were previously submitted to the Examiner in connection with the parent case, Serial No. 08/663,272 filed on November 25, 1996

Consideration of this Information Disclosure Statement is respectfully requested, since the information provided herewith may be material to the examination of the present application as defined under 35 U.S.C. §1.56(a).

Inasmuch as this Information Disclosure Statement is being filed prior to the issuance of a first Office Action on the merits with respect to the above-identified application, no fee or certificate is due.

Respectfully submitted,

  
Leopold Presser  
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343  
PIB/LP:dg

Atty. Docket No.  
10308B

Serial No.

**LIST OF PRIOR ART  
CITED BY APPLICANT**

**Applicants**

Leonard Harrison, et al.

**Filing Date**

January 7, 2002

**Group**

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
	AC						
	AD						
	AE						

		Foreign Document Number	Date	Country	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1.	WO 92/05446	4/2/92	PCT				
	2.	WO 92/14485	9/3/92	PCT				
	3.	WO 92/20811	11/26/92	PCT				
	4.	WO 94/12529	6/9/94	PCT				
	5.	WO 95/07464	3/16/95	PCT				
	6.	WO 95/07992	3/23/95	PCT				

**OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

	7.	Mauch, et al., (1992), "Characterization of a linear epitope within the human pancreatic 64-kDa glutamic acid decarboxylase and its autoimmune recognition by sera from insulin-dependent diabetes mellitus patients", Eur J.Biochem, vol 212:597-603
	8.	Daw et al., (1995), "Two Distinct Glutamic Acid Decarboxylase Auto-Antibody Specificities in IDDM Target Different Epitopes" <u>Diabetes</u> , Vol:44, pp 216-220

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.